![](https://webarchive.library.unt.edu/eot2008/20090115064451im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090115064451im_/http://www.cancer.gov/images/spacer.gif)
larotaxel A semi-synthetic derivative of the taxane 10-deacetylbaccatin III with potential antineoplastic activities. Larotaxel binds to tubulin, promoting microtubule assembly and stabilization and preventing microtubule depolymerization, thereby inhibiting cell proliferation. As it represents poor substrate for P-glycoprotein-related drug resistance mechanisms, this agent may be useful for treating multi-drug resistant tumors. Larotaxel penetrates the blood brain barrier. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090115064451im_/http://www.cancer.gov/images/spacer.gif)
Code names: | ![](https://webarchive.library.unt.edu/eot2008/20090115064451im_/http://www.cancer.gov/images/spacer.gif) | RPR 109881 RPR 109881A XRP9881 | | ![](https://webarchive.library.unt.edu/eot2008/20090115064451im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090115064451im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115064451im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090115064451im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090115064451im_/http://www.cancer.gov/images/spacer.gif) |